Assche GV - Search Results

1

Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept.

Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P, Ceuppens JL. Shen C, et al. Among authors: assche gv. Aliment Pharmacol Ther. 2005 Feb 1;21(3):251-8. doi: 10.1111/j.1365-2036.2005.02309.x. Aliment Pharmacol Ther. 2005. PMID: 15691299 Free article.

2

Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis.

Papamichael K, Baert F, Tops S, Assche GV, Rutgeerts P, Vermeire S, Gils A, Ferrante M. Papamichael K, et al. Among authors: assche gv. J Crohns Colitis. 2017 Jan;11(1):53-59. doi: 10.1093/ecco-jcc/jjw122. Epub 2016 Jul 11. J Crohns Colitis. 2017. PMID: 27402915

3

Maintenance therapy for ulcerative colitis has no impact on changes in the extent of ulcerative colitis.

Eleftheriadis N, Lambrecht G, D'Haens G, Baert F, Cabooter M, Louis E, Assche GV, Schurmans P, Caenepeel P, Outryve MV, Lammens P, Gossum AV, De Vos M; Belgian IBD Research Group. Eleftheriadis N, et al. Among authors: assche gv. J Crohns Colitis. 2007 Sep;1(1):21-7. doi: 10.1016/j.crohns.2007.06.001. J Crohns Colitis. 2007. PMID: 21172180

4

Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach.

Danese S, Banerjee R, Cummings JF, Dotan I, Kotze PG, Leong RWL, Paridaens K, Peyrin-Biroulet L, Scott G, Assche GV, Wehkamp J, Yamamoto-Furusho JK. Danese S, et al. Among authors: assche gv. Intest Res. 2018 Oct;16(4):522-528. doi: 10.5217/ir.2018.00073. Epub 2018 Oct 16. Intest Res. 2018. PMID: 30321913 Free PMC article.

5

Can we influence fibrosis in Crohn's disease?

Assche GV. Assche GV. Acta Gastroenterol Belg. 2001 Apr-Jun;64(2):193-6. Acta Gastroenterol Belg. 2001. PMID: 11475134

6

The optimization of immunosuppressive and biologic cotherapies in inflammatory bowel disease.

Assche GV. Assche GV. Gastroenterol Hepatol (N Y). 2008 Mar;4(3):197-9. Gastroenterol Hepatol (N Y). 2008. PMID: 21904497 Free PMC article. No abstract available.

7

Fecal biomarkers for the diagnosis and management of inflammatory bowel disease.

Assche GV. Assche GV. Gastroenterol Hepatol (N Y). 2011 Jun;7(6):396-8. Gastroenterol Hepatol (N Y). 2011. PMID: 21869871 Free PMC article. No abstract available.

8

Role of biomarkers in the diagnosis of inflammatory bowel disease.

Vermeire S, Assche GV, Rutgeerts P. Vermeire S, et al. Among authors: assche gv. Expert Opin Med Diagn. 2007 Dec;1(4):481-8. doi: 10.1517/17530059.1.4.481. Expert Opin Med Diagn. 2007. PMID: 23496355

9

IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab.

Magdelaine-Beuzelin C, Vermeire S, Goodall M, Baert F, Noman M, Assche GV, Ohresser M, Degenne D, Dugoujon JM, Jefferis R, Rutgeerts P, Lefranc MP, Watier H. Magdelaine-Beuzelin C, et al. Among authors: assche gv. Pharmacogenet Genomics. 2009 May;19(5):383-7. doi: 10.1097/FPC.0b013e32832a06bf. Pharmacogenet Genomics. 2009. PMID: 19319024

10

Balloon dilatation of ileo-colonic anastomosis in Crohn's disease.

Katsanos KH, Rutgeerts PJ, Assche GV, Tsianos EV. Katsanos KH, et al. Among authors: assche gv. Ann Gastroenterol. 2012;25(2):181. Ann Gastroenterol. 2012. PMID: 24714254 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results